162 related articles for article (PubMed ID: 719602)
1. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
Heilmann P; Wagner P; Nawroth PP; Ziegler R
Med Klin (Munich); 2001 Jul; 96(7):371-7. PubMed ID: 11494911
[TBL] [Abstract][Full Text] [Related]
3. Determination of mitotane (o,p-DDD) and its metabolites o,p-DDA and o,p-DDE in plasma by high-performance liquid chromatography.
Andersen A; Kasperlik-Zaluska AA; Warren DJ
Ther Drug Monit; 1999 Jun; 21(3):355-9. PubMed ID: 10365653
[TBL] [Abstract][Full Text] [Related]
4. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
Kasperlik-Zaluska AA; Cichocki A
J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038
[TBL] [Abstract][Full Text] [Related]
5. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
Theile D; Haefeli WE; Weiss J
Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
[TBL] [Abstract][Full Text] [Related]
6. A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients.
Garg MB; Sakoff JA; Ackland SP
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2201-5. PubMed ID: 21719363
[TBL] [Abstract][Full Text] [Related]
7. [The effects of o,p'-DDD on human adrenal steroid synthesis].
Ojima M; Saito M; Fukuchi S
Nihon Naibunpi Gakkai Zasshi; 1984 Jul; 60(7):852-71. PubMed ID: 6094274
[TBL] [Abstract][Full Text] [Related]
8. A high-pressure liquid chromatographic method for measuring mitotane [1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethene in plasma.
Andersen A; Warren DJ; Nome O; Vesterhus L; Slørdal L
Ther Drug Monit; 1995 Oct; 17(5):526-31. PubMed ID: 8585118
[TBL] [Abstract][Full Text] [Related]
9. The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia.
Gebhardt DO; Moolenaar AJ; van Seters AP; van der Velde EA; Gevers Leuven JA
Cancer Chemother Pharmacol; 1992; 29(4):331-4. PubMed ID: 1537084
[TBL] [Abstract][Full Text] [Related]
10. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.
Benecke R; Keller E; Vetter B; de Zeeuw RA
Eur J Clin Pharmacol; 1991; 41(3):259-61. PubMed ID: 1748144
[TBL] [Abstract][Full Text] [Related]
11. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
[TBL] [Abstract][Full Text] [Related]
12. Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment.
Moolenaar AJ; van Slooten H; van Seters AP; Smeenk D
Cancer Chemother Pharmacol; 1981; 7(1):51-4. PubMed ID: 7340988
[TBL] [Abstract][Full Text] [Related]
13. Complete remission of metastasized adrenocortical carcinoma under o,p'-DDD.
Kornely E; Schlaghecke R
Exp Clin Endocrinol; 1994; 102(1):50-3. PubMed ID: 8005209
[TBL] [Abstract][Full Text] [Related]
14. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.
Cusato J; De Francia S; Allegra S; Carrella S; Pirro E; Piccione FM; De Martino F; Ferrero A; Daffara FC; Terzolo M; Berruti A; Di Carlo F; Tampellini M; D'Avolio A
J Pharm Pharmacol; 2017 Nov; 69(11):1524-1530. PubMed ID: 28809444
[TBL] [Abstract][Full Text] [Related]
15. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring.
van Slooten H; Moolenaar AJ; van Seters AP; Smeenk D
Eur J Cancer Clin Oncol; 1984 Jan; 20(1):47-53. PubMed ID: 6537915
[TBL] [Abstract][Full Text] [Related]
16. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements.
Robinson BG; Hales IB; Henniker AJ; Ho K; Luttrell BM; Smee IR; Stiel JN
Clin Endocrinol (Oxf); 1987 Oct; 27(4):437-44. PubMed ID: 2830062
[TBL] [Abstract][Full Text] [Related]
17. Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review.
Boven E; Vermorken JB; van Slooten H; Pinedo HM
Cancer; 1984 Jan; 53(1):26-9. PubMed ID: 6360329
[TBL] [Abstract][Full Text] [Related]
18. Reversible mental deterioration and neurological disturbances with o,p'-DDD therapy.
Bollen E; Lanser JB
Clin Neurol Neurosurg; 1992; 94 Suppl():S49-51. PubMed ID: 1320517
[TBL] [Abstract][Full Text] [Related]
19. Significant regression of the tumor combined with the high level of plasma cortisol by low-dose administration of O, p'-DDD in a case with Cushing's syndrome caused by adrenocortical carcinoma.
Otokida K; Nakamura M; Takeda M; Ito T; Kato M; Masuda T; Tashiro A
Tohoku J Exp Med; 1986 Dec; 150(4):407-15. PubMed ID: 3564003
[TBL] [Abstract][Full Text] [Related]
20. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications.
Lim MC; Tan YO; Chong PY; Cheah JS
Ann Acad Med Singap; 1990 Jul; 19(4):540-4. PubMed ID: 2171414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
